---
title: "Werewolf Reports Q1 Loss Of $13 Mln, Highlights Asset Purchase Agreement With Jazz"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/285710502.md"
description: "Werewolf Therapeutics Inc. reported a Q1 2026 net loss of $13.53 million, improving from a loss of $18.09 million in Q1 2025. R&D expenses decreased to $8.18 million from $13.12 million. The company has $46.50 million in cash and equivalents. Additionally, Werewolf entered an asset purchase agreement with Jazz Pharmaceuticals for global rights to JZP898. The stock closed at $0.62, down 4.64%."
datetime: "2026-05-08T10:55:34.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/285710502.md)
  - [en](https://longbridge.com/en/news/285710502.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/285710502.md)
generator: "portal-rs"
---

# Werewolf Reports Q1 Loss Of $13 Mln, Highlights Asset Purchase Agreement With Jazz

(RTTNews) - Werewolf Therapeutics Inc. (HOWL), a biopharmaceutical company, on Thursday announced the first quarter financial results.

The company specializes in developing conditionally activated therapies that stimulate the body's immune system to treat cancer and immune-mediated diseases. It has developed a proprietary PREDATOR platform, with to design conditionally activated molecules which stimulate the adaptive and innate immune systems to target malignancies. The INDUKINE molecules are activated in the tumor microenvironment, and INDUCER molecules have been developed to target ovarian and prostate cancers.

Q1 2026:

The company reported a net loss of $13.53 million, or $0.28 per share in Q1 2026, while in the same period of 2025 the net loss was $18.09 million, or $0.40 per share.

Research and development expenses (R&D) were $8.18 million, compared to $13.12 million in the previous year.

Cash, cash equivalents, and marketable securities on March 31, 2026, amounted to $46.50 million.

Business Updates:

The company stated that it had entered into an asset purchase agreement with Jazz Pharmaceuticals Ireland Limited. Jazz previously licensed JZP898, an IFNa program, and has now acquired development and commercialization rights globally.

HOWL closed Thursday at $0.62, down 4.64%. 

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

### Related Stocks

- [HOWL.US](https://longbridge.com/en/quote/HOWL.US.md)
- [JAZZ.US](https://longbridge.com/en/quote/JAZZ.US.md)
- [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [NDAQ.US](https://longbridge.com/en/quote/NDAQ.US.md)

## Related News & Research

- [One of Israel Englander's Biotech Picks Just Turned Into a $500M Merger Story](https://longbridge.com/en/news/296626964.md)
- [Werewolf Therapeutics announces USD 150 million oversubscribed private placement of shares, pre-funded warrants](https://longbridge.com/en/news/296615370.md)
- [SBIO: U.S. Programmatic and EMEA drove 49% of Q2 sales, with margins rising to 61% and profitability expected in H2 2026](https://longbridge.com/en/news/296517769.md)
- [Deal Dispatch: MunichRe Buys At-Bay, Mavis Tire Closes Pep Boys Purchase, Werewolf Merges With Ambros](https://longbridge.com/en/news/296641841.md)
- [Werewolf Therapeutics posts Q2 profit on Jazz asset sale](https://longbridge.com/en/news/294503550.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**